Class information for: |
Basic class information |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
| Cluster id | Level | Cluster label | #P |
|---|---|---|---|
| 7 | 4 | CARDIAC & CARDIOVASCULAR SYSTEM//PERIPHERAL VASCULAR DISEASES//CARDIOL | 1572904 |
| 301 | 3 | JOURNAL OF CARDIOVASCULAR PHARMACOLOGY//LEVOSIMENDAN//PHARMACOLOGY & PHARMACY | 41522 |
| 1503 | 2 | NEBIVOLOL//CARVEDILOL//BETA BLOCKERS | 7786 |
| 20799 | 1 | PROPRANOLOL INDUCED BRONCHOCONSTRICTION//CHRONIC OBSTRUCTIVE PULMONARY DISEASE//CARDIOSELECTIVE BETA BLOCKERS | 468 |
Terms with highest relevance score |
| rank | Category | termType | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|---|
| 1 | PROPRANOLOL INDUCED BRONCHOCONSTRICTION | authKW | 240506 | 1% | 71% | 5 |
| 2 | CHRONIC OBSTRUCTIVE PULMONARY DISEASE | authKW | 126975 | 25% | 2% | 117 |
| 3 | CARDIOSELECTIVE BETA BLOCKERS | authKW | 121214 | 1% | 60% | 3 |
| 4 | SECT INTERNAL CARDIO P MED | address | 105216 | 1% | 31% | 5 |
| 5 | ADREAERGIC BETA AGONISTS | authKW | 67343 | 0% | 100% | 1 |
| 6 | AIRWAY RELAXANT RESPONSES | authKW | 67343 | 0% | 100% | 1 |
| 7 | ALPHA RECEPTOR INVERSE AGONIST | authKW | 67343 | 0% | 100% | 1 |
| 8 | AO CLIN PERFEZIONAMENTO | address | 67343 | 0% | 100% | 1 |
| 9 | BETA ADRENOCEPTOR BLOCKERS FEV1 | authKW | 67343 | 0% | 100% | 1 |
| 10 | BETA BLOCKER BETA2 AGONIST COMBINATION | authKW | 67343 | 0% | 100% | 1 |
Web of Science journal categories |
| chi_square_rank | Category | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|
| 1 | Respiratory System | 6521 | 31% | 0% | 145 |
| 2 | Cardiac & Cardiovascular System | 3218 | 33% | 0% | 154 |
| 3 | Critical Care Medicine | 1079 | 10% | 0% | 45 |
| 4 | Medicine, General & Internal | 413 | 15% | 0% | 70 |
| 5 | Pharmacology & Pharmacy | 312 | 17% | 0% | 80 |
| 6 | Allergy | 100 | 2% | 0% | 11 |
| 7 | Geriatrics & Gerontology | 54 | 2% | 0% | 10 |
| 8 | Medicine, Research & Experimental | 16 | 3% | 0% | 16 |
| 9 | Peripheral Vascular Diseases | 7 | 2% | 0% | 9 |
| 10 | Primary Health Care | 5 | 0% | 0% | 2 |
Address terms |
| chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|
| 1 | SECT INTERNAL CARDIO P MED | 105216 | 1% | 31% | 5 |
| 2 | AO CLIN PERFEZIONAMENTO | 67343 | 0% | 100% | 1 |
| 3 | CARDIO PULM REHABIL | 67343 | 0% | 100% | 1 |
| 4 | CARDIOL 2HEART FAILURE UNIT | 67343 | 0% | 100% | 1 |
| 5 | CARDIOL GEORGIA | 67343 | 0% | 100% | 1 |
| 6 | CARDIOL S105 | 67343 | 0% | 100% | 1 |
| 7 | CARDIOPOLMONARE | 67343 | 0% | 100% | 1 |
| 8 | CARDIOTHORAC ANESTHESIA INTENSIVE CARE | 67343 | 0% | 100% | 1 |
| 9 | DOBBS 248D | 67343 | 0% | 100% | 1 |
| 10 | EMERGENCY CRIT CARE CARDIOVASC DIS | 67343 | 0% | 100% | 1 |
Journals |
| chi_square_rank | term | chi_square | shrOfCwithTerm | shrOfTermInClass | termInClass |
|---|---|---|---|---|---|
| 1 | INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 12757 | 3% | 1% | 15 |
| 2 | COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE | 8004 | 2% | 1% | 9 |
| 3 | EUROPEAN JOURNAL OF HEART FAILURE | 7916 | 4% | 1% | 17 |
| 4 | CHEST | 2840 | 6% | 0% | 30 |
| 5 | PULMONARY PHARMACOLOGY & THERAPEUTICS | 2129 | 1% | 0% | 7 |
| 6 | THORAX | 1570 | 3% | 0% | 13 |
| 7 | INTERNATIONAL JOURNAL OF CARDIOLOGY | 1189 | 3% | 0% | 15 |
| 8 | RESPIRATORY MEDICINE | 998 | 2% | 0% | 9 |
| 9 | DRUG INTELLIGENCE & CLINICAL PHARMACY | 965 | 1% | 0% | 4 |
| 10 | JOURNAL OF CARDIAC FAILURE | 948 | 1% | 0% | 5 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Classes with closest relation at Level 1 |